COMMUNIQUÉS West-GlobeNewswire

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
21/02/2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
21/02/2024
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
21/02/2024
CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
BioSyent Named to 2024 TSX Venture 50
21/02/2024
MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top [...]
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
21/02/2024
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind assay to measure target [...]
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21/02/2024
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass [...]
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
21/02/2024
WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
CervoMed to Participate in the BIO CEO and Investor Conference
21/02/2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will [...]
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
21/02/2024
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of [...]
Halo Dental Technologies to Showcase New Digital Dental Mirror at CDS Chicago Midwinter Meeting
21/02/2024
New groundbreaking dental device marks a historic shift in daily-use dental instrument MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Halo Dental Technologies, a pioneering developer of innovative dental technologies, is [...]
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
21/02/2024
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT ™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT ™ study investigator and patient [...]
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
21/02/2024
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT ), (the “Company”), a clinical stage biotechnology company developing [...]
Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia
21/02/2024
Initial Orders for Sharps Securegard 1mL and 3mL Syringes are in Process, Introducing a Line of Competitively Priced, Low Waste, Smart Safety Syringes to the Colombian Healthcare System and the Latin American Market NEW [...]
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
21/02/2024
Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million [...]
Theratechnologies présente ses résultats financiers pour le quatrième trimestre et l’exercice complet 2023 et des prévisions pour 2024
21/02/2024
Le BAIIA* ajusté positif de 5 millions (perte nette de 2,8 millions) de dollars pour le quatrième trimestre de 2023 a été plus de deux fois supérieur à celui du troisième trimestre de 2023, donnant lieu à un [...]
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
21/02/2024
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen [...]
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21/02/2024
— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and [...]
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
21/02/2024
TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License [...]
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
21/02/2024
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings [...]

Pages